Clinical Trial Update: Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating cardiovascular assessment of ponatinib as a third-line treatment in chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Ponatinib (ponatinib)

Snippet

Sponsor: Associazione Italiana Pazienti Leucemia Mieloide Cronica | Conditions: Chronic Myeloid Leukemia (CML) | Phase 2 | Status: UNKNOWN